Compare $ADMA vs $BCRX | Chartloom

Compare

$ADMA vs $BCRX

ADMA Biologics Inc · BioCryst Pharmaceuticals Inc

ADMA

ADMA Biologics Inc

BCRX

BioCryst Pharmaceuticals Inc

Compare $ADMA vs $BCRX

Comparing ADMA Biologics Inc and BioCryst Pharmaceuticals Inc

ADMAADMA Biologics Inc

BCRXBioCryst Pharmaceuticals Inc

ADMAADMA Biologics Inc

Market cap

$2.40B

P/E (TTM)

14.12x

Forward P/E (NTM)

12.78x

Forward P/S (NTM)

4.05x

Rev growth (TTM)

8.0%

YTD performance

-42.1%

52W performance

-29.1%

FCF yield

4.8%

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ADMA

BCRX

Detailed metrics comparison

ADMA

ADMA Biologics Inc

BCRX

BioCryst Pharmaceuticals Inc

Market Cap

ADMA$2.40B

BCRX$2.17B

Enterprise Value

ADMA$2.46B

BCRX$2.84B

Price

ADMA$10.36

BCRX$8.55

P/E Ratio

ADMA14.12x

BCRXN/A

P/S Ratio

ADMA4.69x

BCRX2.31x

EV/Sales

ADMA4.81x

BCRX3.02x

EV/EBITDA

ADMA11.39x

BCRX6.85x

P/B Ratio

ADMA5.33x

BCRX62.13x

P/FCF Ratio

ADMA20.66x

BCRX5.59x

EV/FCF

ADMA21.18x

BCRX7.32x

PEG Ratio

ADMAN/A

BCRXN/A

Forward P/E (NTM)

ADMA12.78x

BCRX16.67x

Forward P/S (NTM)

ADMA4.05x

BCRX3.13x

Revenue (TTM)

ADMA$512M

BCRX$941M

Revenue Growth (YoY)

ADMA8.0%

BCRX68.7%

Forward Rev Growth

ADMA17.6%

BCRX3.9%

Gross Margin (TTM)

ADMA64.7%

BCRX97.8%

Operating Margin (TTM)

ADMA43.4%

BCRX0.0%

EBITDA Margin (TTM)

ADMA42.2%

BCRX41.1%

Net Margin (TTM)

ADMA33.0%

BCRX-40.9%

FCF Margin (TTM)

ADMA22.7%

BCRX41.3%

Net Income (TTM)

ADMA$169M

BCRX$-385M

FCF (TTM)

ADMA$116M

BCRX$388M

EPS (TTM)

ADMA$0.73

BCRX-$1.45

ROE (TTM)

ADMA39.6%

BCRX-32882.0%

ROA (TTM)

ADMA26.6%

BCRX-7758.0%

ROIC (TTM)

ADMA30.1%

BCRX-10666.0%

Cash

ADMA$136M

BCRX$155M

Debt

ADMA$197M

BCRX$824M

Net Cash/Debt

ADMA$-61M

BCRX$-669M

Current Ratio (TTM)

ADMA6.97x

BCRX2.32x

Quick Ratio (TTM)

ADMA3.62x

BCRX2.22x

Debt/Equity (TTM)

ADMA0.48x

BCRX2.26x

Debt/Assets (TTM)

ADMA0.0%

BCRX0.0%

Interest Coverage (TTM)

ADMAN/A

BCRXN/A

Net Debt/EBITDA (TTM)

ADMA0.00x

BCRX0.00x

Beta

ADMA0.70

BCRX0.54

52W Performance

ADMA-29.1%

BCRX17.4%

YTD Performance

ADMA-42.1%

BCRX14.0%

% from 52W High

ADMA-49.4%

BCRX-23.8%

% from 52W Low

ADMA43.7%

BCRX42.5%

Asset Turnover (TTM)

ADMA0.81x

BCRX1.90x

FCF Yield (TTM)

ADMA4.8%

BCRX17.9%

Earnings Yield (TTM)

ADMA7.0%

BCRX-17.7%

Dividend Yield (TTM)

ADMAN/A

BCRXN/A

Rule of 40

ADMA30.7

BCRX110.0

EV/GP/RG

ADMA0.47

BCRX0.74

Ticker research

View ADMA research View BCRX research

Metric	ADMA ADMA Biologics Inc	BCRX BioCryst Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.40B	$2.17B
Enterprise Value	$2.46B	$2.84B
Price	$10.36	$8.55
P/E Ratio	14.12x	N/A
P/S Ratio	4.69x	2.31x
EV/Sales	4.81x	3.02x
EV/EBITDA	11.39x	6.85x
P/B Ratio	5.33x	62.13x
P/FCF Ratio	20.66x	5.59x
EV/FCF	21.18x	7.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	12.78x	16.67x
Forward P/S (NTM)	4.05x	3.13x
Revenue & Growth
Revenue (TTM)	$512M	$941M
Revenue Growth (YoY)	8.0%	68.7%
Forward Rev Growth	17.6%	3.9%
Profitability
Gross Margin (TTM)	64.7%	97.8%
Operating Margin (TTM)	43.4%	0.0%
EBITDA Margin (TTM)	42.2%	41.1%
Net Margin (TTM)	33.0%	-40.9%
FCF Margin (TTM)	22.7%	41.3%
Net Income (TTM)	$169M	$-385M
FCF (TTM)	$116M	$388M
EPS (TTM)	$0.73	-$1.45
ROE (TTM)	39.6%	-32882.0%
ROA (TTM)	26.6%	-7758.0%
ROIC (TTM)	30.1%	-10666.0%
Financial Health
Cash	$136M	$155M
Debt	$197M	$824M
Net Cash/Debt	$-61M	$-669M
Current Ratio (TTM)	6.97x	2.32x
Quick Ratio (TTM)	3.62x	2.22x
Debt/Equity (TTM)	0.48x	2.26x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.70	0.54
52W Performance	-29.1%	17.4%
YTD Performance	-42.1%	14.0%
% from 52W High	-49.4%	-23.8%
% from 52W Low	43.7%	42.5%
Efficiency & Yields
Asset Turnover (TTM)	0.81x	1.90x
FCF Yield (TTM)	4.8%	17.9%
Earnings Yield (TTM)	7.0%	-17.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	30.7	110.0
EV/GP/RG	0.47	0.74
Ticker research	View ADMA research	View BCRX research

Valuation

P/E Ratio

ADMA

14.12x

P/S Ratio

BCRX

2.31x

ADMA

4.69x

EV/FCF

BCRX

7.32x

ADMA

21.18x

Growth & revenue

Revenue Growth TTM

BCRX

68.7%

ADMA

8.0%

Forward Revenue Growth

ADMA

17.6%

BCRX

3.9%

Profitability & performance

Gross Margin

BCRX

97.8%

ADMA

64.7%

ROE

ADMA

39.6%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

ADMA

4.8%

52-Week Performance

BCRX

17.4%

ADMA

-29.1%

Detailed metrics comparison

ADMA

ADMA Biologics Inc

BCRX

BioCryst Pharmaceuticals Inc

Market Cap

ADMA$2.40B

BCRX$2.17B

Enterprise Value

ADMA$2.46B

BCRX$2.84B

Price

ADMA$10.36

BCRX$8.55

P/E Ratio

ADMA14.12x

BCRXN/A

P/S Ratio

ADMA4.69x

BCRX2.31x

EV/Sales

ADMA4.81x

BCRX3.02x

EV/EBITDA

ADMA11.39x

BCRX6.85x

P/B Ratio

ADMA5.33x

BCRX62.13x

P/FCF Ratio

ADMA20.66x

BCRX5.59x

EV/FCF

ADMA21.18x

BCRX7.32x

PEG Ratio

ADMAN/A

BCRXN/A

Forward P/E (NTM)

ADMA12.78x

BCRX16.67x

Forward P/S (NTM)

ADMA4.05x

BCRX3.13x

Revenue (TTM)

ADMA$512M

BCRX$941M

Revenue Growth (YoY)

ADMA8.0%

BCRX68.7%

Forward Rev Growth

ADMA17.6%

BCRX3.9%

Gross Margin (TTM)

ADMA64.7%

BCRX97.8%

Operating Margin (TTM)

ADMA43.4%

BCRX0.0%

EBITDA Margin (TTM)

ADMA42.2%

BCRX41.1%

Net Margin (TTM)

ADMA33.0%

BCRX-40.9%

FCF Margin (TTM)

ADMA22.7%

BCRX41.3%

Net Income (TTM)

ADMA$169M

BCRX$-385M

FCF (TTM)

ADMA$116M

BCRX$388M

EPS (TTM)

ADMA$0.73

BCRX-$1.45

ROE (TTM)

ADMA39.6%

BCRX-32882.0%

ROA (TTM)

ADMA26.6%

BCRX-7758.0%

ROIC (TTM)

ADMA30.1%

BCRX-10666.0%

Cash

ADMA$136M

BCRX$155M

Debt

ADMA$197M

BCRX$824M

Net Cash/Debt

ADMA$-61M

BCRX$-669M

Current Ratio (TTM)

ADMA6.97x

BCRX2.32x

Quick Ratio (TTM)

ADMA3.62x

BCRX2.22x

Debt/Equity (TTM)

ADMA0.48x

BCRX2.26x

Debt/Assets (TTM)

ADMA0.0%

BCRX0.0%

Interest Coverage (TTM)

ADMAN/A

BCRXN/A

Net Debt/EBITDA (TTM)

ADMA0.00x

BCRX0.00x

Beta

ADMA0.70

BCRX0.54

52W Performance

ADMA-29.1%

BCRX17.4%

YTD Performance

ADMA-42.1%

BCRX14.0%

% from 52W High

ADMA-49.4%

BCRX-23.8%

% from 52W Low

ADMA43.7%

BCRX42.5%

Asset Turnover (TTM)

ADMA0.81x

BCRX1.90x

FCF Yield (TTM)

ADMA4.8%

BCRX17.9%

Earnings Yield (TTM)

ADMA7.0%

BCRX-17.7%

Dividend Yield (TTM)

ADMAN/A

BCRXN/A

Rule of 40

ADMA30.7

BCRX110.0

EV/GP/RG

ADMA0.47

BCRX0.74

Ticker research

View ADMA research View BCRX research

Metric	ADMA ADMA Biologics Inc	BCRX BioCryst Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.40B	$2.17B
Enterprise Value	$2.46B	$2.84B
Price	$10.36	$8.55
P/E Ratio	14.12x	N/A
P/S Ratio	4.69x	2.31x
EV/Sales	4.81x	3.02x
EV/EBITDA	11.39x	6.85x
P/B Ratio	5.33x	62.13x
P/FCF Ratio	20.66x	5.59x
EV/FCF	21.18x	7.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	12.78x	16.67x
Forward P/S (NTM)	4.05x	3.13x
Revenue & Growth
Revenue (TTM)	$512M	$941M
Revenue Growth (YoY)	8.0%	68.7%
Forward Rev Growth	17.6%	3.9%
Profitability
Gross Margin (TTM)	64.7%	97.8%
Operating Margin (TTM)	43.4%	0.0%
EBITDA Margin (TTM)	42.2%	41.1%
Net Margin (TTM)	33.0%	-40.9%
FCF Margin (TTM)	22.7%	41.3%
Net Income (TTM)	$169M	$-385M
FCF (TTM)	$116M	$388M
EPS (TTM)	$0.73	-$1.45
ROE (TTM)	39.6%	-32882.0%
ROA (TTM)	26.6%	-7758.0%
ROIC (TTM)	30.1%	-10666.0%
Financial Health
Cash	$136M	$155M
Debt	$197M	$824M
Net Cash/Debt	$-61M	$-669M
Current Ratio (TTM)	6.97x	2.32x
Quick Ratio (TTM)	3.62x	2.22x
Debt/Equity (TTM)	0.48x	2.26x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.70	0.54
52W Performance	-29.1%	17.4%
YTD Performance	-42.1%	14.0%
% from 52W High	-49.4%	-23.8%
% from 52W Low	43.7%	42.5%
Efficiency & Yields
Asset Turnover (TTM)	0.81x	1.90x
FCF Yield (TTM)	4.8%	17.9%
Earnings Yield (TTM)	7.0%	-17.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	30.7	110.0
EV/GP/RG	0.47	0.74
Ticker research	View ADMA research	View BCRX research